Use

The PD-L1, IHC test is used to evaluate programmed cell death-ligand 1 (PD-L1) expression in tumor tissues. PD-L1 is an immune inhibitory receptor ligand expressed by tumor cells and tumor-associated immune cells. This test is particularly significant for patients undergoing treatment with nivolumab, as PD-L1 expression on tumor cells can help predict response to therapy in cases of non-small-cell lung cancer. This immunohistochemical evaluation aids in the selection of suitable candidates for immune checkpoint inhibitors, potentially improving treatment outcomes by identifying tumors that may respond to nivolumab treatment.